Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors acting as LDL-lowering agents ...

Since 2019, PCSK9i have had a label expansion; positive results from major outcomes trials and large studies showing the use of PCSK9 inhibitors reducing cardiac events; a 60% price reduction on ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780 ... that is compatible with traditional oral small molecule drug discovery,” said Sharon Barr, AZ ...

including statins and PCSK9 inhibitors – and that the majority of those cases are associated with Lp(a). CSPC's drug differs from the others, as it is a small-molecule compound and orally ...